DMTKDermTech, Inc.

Nasdaq dermtech.com


$ 0.60 $ 0.02 (3.02 %)    

Friday, 26-Apr-2024 15:16:11 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 0.6031
$ 0.60
$ 0.00 x 0
$ 0.00 x 0
$ 0.60 - $ 0.60
$ 0.58 - $ 3.90
87,187
na
19.69M
$ 2.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-29-2024 12-31-2023 10-K
2 11-02-2023 09-30-2023 10-Q
3 08-03-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 03-02-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-03-2022 03-31-2022 10-Q
9 03-10-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-04-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-05-2021 12-31-2020 10-K
14 11-10-2020 09-30-2020 10-Q
15 08-05-2020 06-30-2020 10-Q
16 05-13-2020 03-31-2020 10-Q
17 03-11-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-13-2019 06-30-2019 10-Q
20 06-14-2019 03-31-2019 10-K
21 02-14-2019 12-31-2018 10-Q
22 11-14-2018 09-30-2018 10-Q
23 08-10-2018 06-30-2018 10-Q
24 06-29-2018 03-31-2018 10-K
25 02-13-2018 12-31-2017 10-Q
26 11-13-2017 09-30-2017 10-Q
27 08-14-2017 06-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lake-street-downgrades-dermtech-to-hold-announces-063-price-target

Lake Street analyst Thomas Flaten downgrades DermTech (NASDAQ:DMTK) from Buy to Hold and announces $0.63 price target.

 stephens--co-reiterates-equal-weight-on-dermtech-maintains-15-price-target

Stephens & Co. analyst Mason Carrico reiterates DermTech (NASDAQ:DMTK) with a Equal-Weight and maintains $1.5 price target.

 btig-downgrades-dermtech-to-neutral

BTIG analyst Sung Ji Nam downgrades DermTech (NASDAQ:DMTK) from Buy to Neutral.

 dermtech-intends-to-continue-laboratory-operations-during-strategic-review

The Company anticipates incurring a one-time restructuring charge of approximately $1.6 million in the second quarter of 2024 i...

 dermtech-to-seek-strategic-alternatives-plans-restructuring-actions-that-will-result-in-workforce-reduction-of-100-employees-or-56-of-workforce

Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business com...

 btig-maintains-buy-on-dermtech-lowers-price-target-to-2

BTIG analyst Mark Massaro maintains DermTech (NASDAQ:DMTK) with a Buy and lowers the price target from $4 to $2.

 stephens--co-maintains-equal-weight-on-dermtech-lowers-price-target-to-15

Stephens & Co. analyst Mason Carrico maintains DermTech (NASDAQ:DMTK) with a Equal-Weight and lowers the price target fr...

 why-zscaler-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

 recap-dermtech-q4-earnings
Recap: DermTech Q4 Earnings
02/29/2024 21:05:18

 dermtech-q4-2023-gaap-eps-0560-beats-0570-estimate-sales-3924m-miss-4044m-estimate

DermTech (NASDAQ:DMTK) reported quarterly losses of $(0.560) per share which beat the analyst consensus estimate of $(0.570) by...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

 dermtech-discontinus-optional-tert-add-on-assay-for-dermtech-melanoma-test

- Trust 2 Study confirms negative predictive value (NPV) of 99.7% for the foundational gene expression assay- Optional TERT pro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION